Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle-Based Blood Test: Performance in a Training and Verification Cohort.

Autor:	Winn-Deen ES; Mercy BioAnalytics Inc., Waltham, Massachusetts. Electronic address: emily@mercybio.com., Bortolin LT; Mercy BioAnalytics Inc., Waltham, Massachusetts., Gusenleitner D; Mercy BioAnalytics Inc., Waltham, Massachusetts., Biette KM; Mercy BioAnalytics Inc., Waltham, Massachusetts., Copeland K; Boulder Statistics, Boulder, Colorado., Gentry-Maharaj A; MRC Clinical Trials Unit, Institute for Clinical Trials and Methodology, University College London, London, United Kingdom; Department of Women's Cancer, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom., Apostolidou S; MRC Clinical Trials Unit, Institute for Clinical Trials and Methodology, University College London, London, United Kingdom., Couvillon AD; Mercy BioAnalytics Inc., Waltham, Massachusetts., Salem DP; Mercy BioAnalytics Inc., Waltham, Massachusetts., Banerjee S; Mercy BioAnalytics Inc., Waltham, Massachusetts., Grosha J; Mercy BioAnalytics Inc., Waltham, Massachusetts., Zabroski IO; Mercy BioAnalytics Inc., Waltham, Massachusetts., Sedlak CR; Mercy BioAnalytics Inc., Waltham, Massachusetts., Byrne DM; Mercy BioAnalytics Inc., Waltham, Massachusetts., Hamzeh BF; Mercy BioAnalytics Inc., Waltham, Massachusetts., King MS; Mercy BioAnalytics Inc., Waltham, Massachusetts., Cuoco LT; Mercy BioAnalytics Inc., Waltham, Massachusetts., Duff PA; Mercy BioAnalytics Inc., Waltham, Massachusetts., Manning BJ; Mercy BioAnalytics Inc., Waltham, Massachusetts., Hawkins TB; Mercy BioAnalytics Inc., Waltham, Massachusetts., Mattoon D; Mercy BioAnalytics Inc., Waltham, Massachusetts., Guettouche T; Mercy BioAnalytics Inc., Waltham, Massachusetts., Skates SJ; MGH Biostatistics, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts., Jamieson A; Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of British Columbia and BC Cancer, Vancouver, British Columbia, Canada., McAlpine JN; Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of British Columbia and BC Cancer, Vancouver, British Columbia, Canada., Huntsman D; Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of British Columbia and BC Cancer, Vancouver, British Columbia, Canada; Department of Pathology, University of British Columbia and BC Cancer, Vancouver, British Columbia, Canada., Menon U; MRC Clinical Trials Unit, Institute for Clinical Trials and Methodology, University College London, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	The Journal of molecular diagnostics : JMD [J Mol Diagn] 2024 Sep 24. Date of Electronic Publication: 2024 Sep 24.
DOI:	10.1016/j.jmoldx.2024.09.001
Abstrakt:	The low incidence of ovarian cancer (OC) dictates that any screening strategy needs to be both highly sensitive and highly specific. This study explored the utility of detecting multiple colocalized proteins or glycosylation epitopes on single tumor-associated extracellular vesicles from blood. The novel Mercy Halo Ovarian Cancer Test (OC Test) uses immunoaffinity capture of tumor-associated extracellular vesicles, followed by proximity-ligation real-time quantitative PCR to detect combinations of up to three biomarkers to maximize specificity and measures multiple combinations to maximize sensitivity. A high-grade serous carcinoma (HGSC) case-control training set of EDTA plasma samples from 397 women was used to lock down the test design, the data interpretation algorithm, and the cutoff between cancer and noncancer. Performance was verified and compared with cancer antigen 125 in an independent blinded case-control set of serum samples from 390 women (132 controls, 66 HGSC, 83 non-HGSC OC, and 109 benign). In the verification study, the OC Test showed a specificity of 97.0% (128/132; 95% CI, 92.4%-99.6%), a HGSC sensitivity of 97.0% (64/66; 95% CI, 87.8%-99.2%), and an area under the curve of 0.97 (95% CI, 0.93-0.99) and detected 73.5% (61/83; 95% CI, 62.7%-82.6%) of the non-HGSC OC cases. This test exhibited fewer false positives in subjects with benign ovarian tumors, nonovarian cancers, and inflammatory conditions when compared with cancer antigen 125. The combined sensitivity and specificity of this new test suggests it may have potential in OC screening. Competing Interests: Disclosure Statement L.T.B., A.D.C., D.P.S., S.B., I.O.Z., D.M.B., M.S.K., L.T.C., B.J.M., T.B.H., T.G., and D.M. are current employees of Mercy BioAnalytics Inc. E.S.W.-D. is a retired Mercy BioAnalytics employee and is currently a paid consultant of Mercy BioAnalytics Inc. She was a full-time employee when this work was performed. K.M.B., P.A.D., J.G., D.G., B.F.H., and C.R.S. are former employees of Mercy BioAnalytics Inc., who were active employees at the time this work was performed. S.J.S. and K.C. are paid consultants for Mercy BioAnalytics Inc. A.J., J.N.M., and D.H. are employees of University of British Columbia and provided the patient samples used for the training study. A.G.-M., S.A., and U.M. are employees of University College London and provided the patient samples used for the verification study. They also report research collaborations with Cambridge University, QIMR Berghofer Medical Research Institute, Intelligent Lab on Fiber, RNA Guardian, Micronoma, Imperial College London, University of Innsbruck, and Dana Farber USA in the area of early detection of cancer. U.M. had stock ownership (2011 to 2021) awarded by University College London in Abcodia, which held the license for the Risk of Ovarian Cancer Algorithm. She has received grant funding from the Medical Research Council, Cancer Research UK, the National Institute for Health Research UK, the Eve Appeal, and the Australian National Health and Medical Research Council. She is also a member of Tina's Wish Scientific Advisory Board (United States) and the Research Advisory Panel, Yorkshire Cancer Research (United Kingdom). L.T.B. and D.P.S. are inventors on US patent number 11,085,089 B2, Systems, Compositions and Methods for Target Entity Detection (issued August 10, 2021). L.T.B., D.P.S., E.S.W.-D., D.G., K.M.B., and A.D.C. are inventors on US patent application 63/417309, Composition and Methods for Detection of Ovarian Cancer (filed October 18, 2022). U.M. holds patent number EP10178345.4 for Breast Cancer Diagnostics. (Copyright © 2024. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu